Cargando…
Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function
STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-f...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970730/ https://www.ncbi.nlm.nih.gov/pubmed/33582778 http://dx.doi.org/10.1093/humrep/deaa342 |
_version_ | 1783666468800430080 |
---|---|
author | van der Kooi, Anne-Lotte L F van Dijk, Marloes Broer, Linda van den Berg, Marleen H Laven, Joop S E van Leeuwen, Flora E Lambalk, Cornelis B Overbeek, Annelies Loonen, Jacqueline J van der Pal, Helena J Tissing, Wim J Versluys, Birgitta Bresters, Dorine Beerendonk, Catharina C M Ronckers, Cécile R van der Heiden-van der Loo, Margriet Kaspers, Gertjan L de Vries, Andrica C H Robison, Leslie L Hudson, Melissa M Chemaitilly, Wassim Byrne, Julianne Berger, Claire Clemens, Eva Dirksen, Uta Falck Winther, Jeanette Fosså, Sophie D Grabow, Desiree Haupt, Riccardo Kaiser, Melanie Kepak, Tomas Kruseova, Jarmila Modan-Moses, Dalit Pluijm, Saskia M F Spix, Claudia Zolk, Oliver Kaatsch, Peter Krijthe, Jesse H Kremer, Leontien C Yasui, Yutaka Brooke, Russell J Uitterlinden, André G van den Heuvel-Eibrink, Marry M van Dulmen-den Broeder, Eline |
author_facet | van der Kooi, Anne-Lotte L F van Dijk, Marloes Broer, Linda van den Berg, Marleen H Laven, Joop S E van Leeuwen, Flora E Lambalk, Cornelis B Overbeek, Annelies Loonen, Jacqueline J van der Pal, Helena J Tissing, Wim J Versluys, Birgitta Bresters, Dorine Beerendonk, Catharina C M Ronckers, Cécile R van der Heiden-van der Loo, Margriet Kaspers, Gertjan L de Vries, Andrica C H Robison, Leslie L Hudson, Melissa M Chemaitilly, Wassim Byrne, Julianne Berger, Claire Clemens, Eva Dirksen, Uta Falck Winther, Jeanette Fosså, Sophie D Grabow, Desiree Haupt, Riccardo Kaiser, Melanie Kepak, Tomas Kruseova, Jarmila Modan-Moses, Dalit Pluijm, Saskia M F Spix, Claudia Zolk, Oliver Kaatsch, Peter Krijthe, Jesse H Kremer, Leontien C Yasui, Yutaka Brooke, Russell J Uitterlinden, André G van den Heuvel-Eibrink, Marry M van Dulmen-den Broeder, Eline |
author_sort | van der Kooi, Anne-Lotte L F |
collection | PubMed |
description | STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy. WHAT IS KNOWN ALREADY: Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability. STUDY DESIGN, SIZE, DURATION: CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the discovery Dutch DCOG-LATER VEVO cohort (n = 285) were validated in the pan-European PanCareLIFE (n = 465) and the USA-based St. Jude Lifetime Cohort (n = 391). PARTICIPANTS/MATERIALS, SETTING, METHODS: To evaluate ovarian function, anti-Müllerian hormone (AMH) levels were assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their impact on ovarian function. Results were then examined using fixed-effect meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Meta-analysis across the three independent cohorts showed a significant interaction effect (P = 3.0 × 10(−4)) between rs11668344 of BRSK1 (allele frequency = 0.34) among CCS treated with high-dose alkylating agents (CED score ≥8000 mg/m(2)), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00). LIMITATIONS, REASONS FOR CAUTION: While low AMH levels can also identify poor responders in assisted reproductive technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function. WIDER IMPLICATIONS OF THE FINDINGS: Further research, validating our findings and identifying additional risk-contributing genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in girls with cancer. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the PanCareLIFE project that has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. In addition, the DCOG-LATER VEVO study was funded by the Dutch Cancer Society (Grant no. VU 2006-3622) and by the Children Cancer Free Foundation (Project no. 20) and the St Jude Lifetime cohort study by NCI U01 CA195547. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A. |
format | Online Article Text |
id | pubmed-7970730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79707302021-03-23 Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function van der Kooi, Anne-Lotte L F van Dijk, Marloes Broer, Linda van den Berg, Marleen H Laven, Joop S E van Leeuwen, Flora E Lambalk, Cornelis B Overbeek, Annelies Loonen, Jacqueline J van der Pal, Helena J Tissing, Wim J Versluys, Birgitta Bresters, Dorine Beerendonk, Catharina C M Ronckers, Cécile R van der Heiden-van der Loo, Margriet Kaspers, Gertjan L de Vries, Andrica C H Robison, Leslie L Hudson, Melissa M Chemaitilly, Wassim Byrne, Julianne Berger, Claire Clemens, Eva Dirksen, Uta Falck Winther, Jeanette Fosså, Sophie D Grabow, Desiree Haupt, Riccardo Kaiser, Melanie Kepak, Tomas Kruseova, Jarmila Modan-Moses, Dalit Pluijm, Saskia M F Spix, Claudia Zolk, Oliver Kaatsch, Peter Krijthe, Jesse H Kremer, Leontien C Yasui, Yutaka Brooke, Russell J Uitterlinden, André G van den Heuvel-Eibrink, Marry M van Dulmen-den Broeder, Eline Hum Reprod Original Articles STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy. WHAT IS KNOWN ALREADY: Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability. STUDY DESIGN, SIZE, DURATION: CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the discovery Dutch DCOG-LATER VEVO cohort (n = 285) were validated in the pan-European PanCareLIFE (n = 465) and the USA-based St. Jude Lifetime Cohort (n = 391). PARTICIPANTS/MATERIALS, SETTING, METHODS: To evaluate ovarian function, anti-Müllerian hormone (AMH) levels were assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their impact on ovarian function. Results were then examined using fixed-effect meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Meta-analysis across the three independent cohorts showed a significant interaction effect (P = 3.0 × 10(−4)) between rs11668344 of BRSK1 (allele frequency = 0.34) among CCS treated with high-dose alkylating agents (CED score ≥8000 mg/m(2)), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00). LIMITATIONS, REASONS FOR CAUTION: While low AMH levels can also identify poor responders in assisted reproductive technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function. WIDER IMPLICATIONS OF THE FINDINGS: Further research, validating our findings and identifying additional risk-contributing genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in girls with cancer. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the PanCareLIFE project that has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. In addition, the DCOG-LATER VEVO study was funded by the Dutch Cancer Society (Grant no. VU 2006-3622) and by the Children Cancer Free Foundation (Project no. 20) and the St Jude Lifetime cohort study by NCI U01 CA195547. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A. Oxford University Press 2021-02-14 /pmc/articles/PMC7970730/ /pubmed/33582778 http://dx.doi.org/10.1093/humrep/deaa342 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles van der Kooi, Anne-Lotte L F van Dijk, Marloes Broer, Linda van den Berg, Marleen H Laven, Joop S E van Leeuwen, Flora E Lambalk, Cornelis B Overbeek, Annelies Loonen, Jacqueline J van der Pal, Helena J Tissing, Wim J Versluys, Birgitta Bresters, Dorine Beerendonk, Catharina C M Ronckers, Cécile R van der Heiden-van der Loo, Margriet Kaspers, Gertjan L de Vries, Andrica C H Robison, Leslie L Hudson, Melissa M Chemaitilly, Wassim Byrne, Julianne Berger, Claire Clemens, Eva Dirksen, Uta Falck Winther, Jeanette Fosså, Sophie D Grabow, Desiree Haupt, Riccardo Kaiser, Melanie Kepak, Tomas Kruseova, Jarmila Modan-Moses, Dalit Pluijm, Saskia M F Spix, Claudia Zolk, Oliver Kaatsch, Peter Krijthe, Jesse H Kremer, Leontien C Yasui, Yutaka Brooke, Russell J Uitterlinden, André G van den Heuvel-Eibrink, Marry M van Dulmen-den Broeder, Eline Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function |
title | Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function |
title_full | Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function |
title_fullStr | Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function |
title_full_unstemmed | Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function |
title_short | Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function |
title_sort | possible modification of brsk1 on the risk of alkylating chemotherapy-related reduced ovarian function |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970730/ https://www.ncbi.nlm.nih.gov/pubmed/33582778 http://dx.doi.org/10.1093/humrep/deaa342 |
work_keys_str_mv | AT vanderkooiannelottelf possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vandijkmarloes possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT broerlinda possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vandenbergmarleenh possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT lavenjoopse possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vanleeuwenflorae possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT lambalkcornelisb possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT overbeekannelies possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT loonenjacquelinej possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vanderpalhelenaj possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT tissingwimj possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT versluysbirgitta possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT brestersdorine possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT beerendonkcatharinacm possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT ronckersceciler possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vanderheidenvanderloomargriet possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT kaspersgertjanl possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT devriesandricach possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT robisonlesliel possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT hudsonmelissam possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT chemaitillywassim possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT byrnejulianne possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT bergerclaire possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT clemenseva possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT dirksenuta possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT falckwintherjeanette possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT fossasophied possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT grabowdesiree possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT hauptriccardo possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT kaisermelanie possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT kepaktomas possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT kruseovajarmila possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT modanmosesdalit possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT pluijmsaskiamf possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT spixclaudia possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT zolkoliver possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT kaatschpeter possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT krijthejesseh possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT kremerleontienc possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT yasuiyutaka possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT brookerussellj possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT uitterlindenandreg possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vandenheuveleibrinkmarrym possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction AT vandulmendenbroedereline possiblemodificationofbrsk1ontheriskofalkylatingchemotherapyrelatedreducedovarianfunction |